{"organizations": [], "uuid": "921cec6d076ad8c6ffa58052b56461b5d3fb9976", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180426.html", "section_title": "Archive News &amp; Video for Thursday, 26 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-theranexus-fy-net-loss-widens-to-2/brief-theranexus-fy-net-loss-widens-to-2-1-million-euros-idUSFWN1S31NU", "country": "US", "domain_rank": 408, "title": "Theranexus FY Net Loss Widens To 2.1 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.92, "site_type": "news", "published": "2018-04-27T01:21:00.000+03:00", "replies_count": 0, "uuid": "921cec6d076ad8c6ffa58052b56461b5d3fb9976"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-theranexus-fy-net-loss-widens-to-2/brief-theranexus-fy-net-loss-widens-to-2-1-million-euros-idUSFWN1S31NU", "ord_in_thread": 0, "title": "Theranexus FY Net Loss Widens To 2.1 Million Euros", "locations": [], "entities": {"persons": [{"name": "theranexus", "sentiment": "negative"}, {"name": "parkinson", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 26 (Reuters) - THERANEXUS SA:\n* FY OPERATING LOSS EUR 2.7 MILLION VERSUS EUR 2.1 MILLION YEAR AGO\n* FY NET LOSS EUR 2.1 MILLION VERSUS LOSS OF EUR 1.6 MILLION YEAR AGO\n* END-DEC CASH AND CASH EQUIVALENTS EUR 18.2 MILLION\n* WE ARE ACCELERATING OUR CLINICAL DEVELOPMENTS IN 2018, WITH IMPORTANT FIRST MILESTONES - CEO\n* 2018 MILESTONES: OBTAINING APPROVALS FOR PHASE 2 CLINICAL TRIALS FOR THN102 IN PARKINSONâ€™S DISEASE IN A FIRST EUROPEAN COUNTRY AND IN UNITED STATES - CEO Source text for Eikon: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-27T01:21:00.000+03:00", "crawled": "2018-04-27T16:35:40.001+03:00", "highlightTitle": ""}